Glycedil Duo^®

Glycedil Duo combines Sitagliptin and Metformin in an oral-release tablet, specifically designed for the management of type 2 diabetes in adults. This combination takes advantage of the complementary mechanisms of both drugs to improve glycemic control, with a low risk of hypoglycemia when used without insulin or sulfonylureas.

Glycedil Duo is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, particularly in patients inadequately controlled on metformin alone or those already receiving sitagliptin and metformin in combination.

Sitagliptin is a DPP-4 inhibitor that increases the levels of incretin hormones, improving insulin secretion and reducing glucagon. Metformin improves insulin sensitivity and reduces hepatic glucose production. Together, they offer effective control of postprandial and basal glucose.

Dosage should be personalized based on the patient’s current response to treatment. Typical starting dose: one tablet containing Sitagliptin 50 mg and Metformin 1000 mg twice daily, with meals to reduce gastrointestinal effects. Dose adjustments may include increases up to Sitagliptin 100 mg and Metformin 1000 mg twice daily according to need and tolerance.

The combination in a single tablet facilitates treatment adherence, reducing the daily medication burden. Improves glycemic control more effectively than monotherapy with either component. Associated with a low risk of hypoglycemia compared with other antidiabetic agents.

Start treatment only after evaluating renal function and verifying the adequacy of the patient’s diet and exercise. Adjust the dose based on blood glucose control and the patient’s tolerance. Monitor renal function regularly, especially in elderly patients or those at risk of renal impairment.

Monitor renal function at least once a year, or more frequently in patients with risk factors for renal impairment. Use with caution in patients at risk of lactic acidosis, especially those with renal or hepatic insufficiency. Contraindicated in patients with severe renal insufficiency, active liver disease or metabolic acidosis, including diabetic ketoacidosis.

Glycedil Duo is available as Sitagliptin 100 mg / Metformin 1000 mg and Sitagliptin 50 mg / Metformin 1000 mg, in a box of 30 tablets, following the British Pharmacopoeia standard.

Glycedil Duo is manufactured according to the strict specifications of the British Pharmacopoeia to ensure consistency and superior quality. Crassula Pharma certifies that all its products are manufactured in accordance with GMP parameters.